C4 Therapeutics, Inc.宣布,其针对复发/难治性多发性骨髓瘤的1B期临床试验已完成首位患者给药。该试验旨在评估Cemsidomide与Elranatamab(商品名:Elrexfio®)联合疗法的安全性与有效性。
C4 Therapeutics, Inc.宣布,其针对复发/难治性多发性骨髓瘤的1B期临床试验已完成首位患者给药。该试验旨在评估Cemsidomide与Elranatamab(商品名:Elrexfio®)联合疗法的安全性与有效性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.